Genocea Biosciences Inc. buy Heureka
Summary
This prediction ended on 16.03.20 with a price of €1.36. The prediction for Genocea Biosciences Inc. disappointed with a performance of -14.47%. Heureka has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | 0,18 % | 5,07 % | 8,98 % | 63,88 % |
| iShares Nasdaq 100 | -0,77 % | -2,08 % | 26,44 % | 88,09 % |
| iShares Nikkei 225® | 0,73 % | -3,35 % | 47,89 % | 78,01 % |
| iShares S&P 500 | -0,17 % | 0,90 % | 22,97 % | 69,45 % |
Comments by Heureka for this prediction
In the thread Genocea Biosciences Inc. diskutieren